The Chemours Company offers its customers with solutions across a vast spectrum of industries including plastics and coatings, refrigeration and air conditioning, mining and general industrial manufacturing and electronics. The company's major products include titanium dioxide (TiO2), refrigerants, industrial fluoropolymer resins and sodium cyanide. The company has manufacturing sites catering to customers across North America, Latin America, Asia-Pacific and Europe. It currently has four reportable segments: Titanium Technologies, Thermal & Specialized Solutions (formerly known as Fluoroproducts), Advanced Performance Materials (formerly known as Fluoropolymers) and Chemical Solutions....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 20 December 2025
2018-05-10 07:37:00 Thursday ET

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions in their recent corporate disclosures as of mid-2018. Georg
2019-02-13 11:00:00 Wednesday ET

President Trump may reluctantly sign the congressional border wall deal in order to avert another U.S. government shutdown. With his executive power to decl
2018-05-13 08:33:00 Sunday ET

Incoming New York Fed President John Williams suggests that it is about time to end forward guidance in order to stop holding the financial market's han
2017-07-07 10:33:00 Friday ET

Warren Buffett invests in American stocks across numerous industries such as energy, air transport, finance, technology, retail provision, and so forth.
2025-10-02 12:31:00 Thursday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be